We are live on ! Find out more
LAB icon

Standard BioTools

121 hedge funds and large institutions have $220M invested in Standard BioTools in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 33 increasing their positions, 44 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more call options, than puts

Call options by funds: $1.92M | Put options by funds: $987K

16% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 19

2% more funds holding

Funds holding: 119121 (+2)

3.39% less ownership

Funds ownership: 76.98%73.59% (-3.4%)

25% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 44

43% less capital invested

Capital invested by funds: $387M → $220M (-$166M)

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
121
Holders Change
+2
Holders Change %
+1.68%
% of All Funds
1.86%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
22
Increased
33
Reduced
44
Closed
19
Calls
$1.92M
Puts
$987K
Net Calls
+$937K
Net Calls Change
-$1.79M

LAB Hedge Fund Activity: Q4 2021 in Review

121 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q4 2021, worth a combined $220M — down 43% from $387M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new LAB positions and 19 closed out — a net gain of 3 holders — while 33 added to existing stakes and 44 trimmed.

The largest buyer was Balyasny Asset Management, adding an estimated $1.78M. The largest seller was Millennium Management, cutting an estimated $10.6M.

  • 121 institutional investors held Standard BioTools (LAB) as of Q4 2021, up from 119 in Q3 2021.
  • Funds reported $220M of Standard BioTools stock for Q4 2021, down 43% quarter-over-quarter.
  • 22 funds opened new Standard BioTools positions in Q4 2021 and 19 closed out, a net change of +3 holders.
  • The largest Standard BioTools buyer in Q4 2021 was Balyasny Asset Management, an estimated $1.78M added.
  • The largest Standard BioTools seller in Q4 2021 was Millennium Management, an estimated $10.6M sold.

Based on aggregated 13F filings for Q4 2021.